UK & Europe NICE says Otezla's bargain price offsets lower efficacy Otezla cheap and convenient, but less effective than rivals, says NICE.
News Janssen's RA candidate among hot topics at EULAR But attendees warned to expect "oceanic" weather.
News Biogen eyeing big-selling biosimilars as MS drug fails Gamble on opicinumab looks unlikely to pay off.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
